Clinical relevance of the HLA system in blood transfusion

Vox Sanguinis

Volumn 101, Issue 2, 2011, Pages 93-105

  Brown, C J ^a   Navarrete, C V ^b  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antigen; Human; Immune; Leukocyte; Reactions; Transfusion

Indexed keywords

HEAT SHOCK PROTEIN; HLA A ANTIGEN; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B ANTIGEN; HLA C ANTIGEN; HLA DM ANTIGEN; HLA DMA ANTIGEN; HLA DMB ANTIGEN; HLA DO ANTIGEN; HLA DOA ANTIGEN; HLA DOB ANTIGEN; HLA DP ANTIGEN; HLA DPA1 ANTIGEN; HLA DPB1 ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; HLA E ANTIGEN; HLA F ANTIGEN; HLA G ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M; LOW MOLECULAR WEIGHT PROTEASOME; PROTEASOME; TAPASIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNIZATION; ANAPHYLAXIS; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ANTIGEN EXPRESSION; APLASTIC ANEMIA; B LYMPHOCYTE; BLOOD COMPATIBILITY; BLOOD GROUP ABO SYSTEM; BLOOD GROUP TYPING; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOTROPHOBLAST; DIFFERENTIAL DIAGNOSIS; DNA FINGERPRINTING; DNA POLYMORPHISM; DNA SEQUENCING BASED TYPING; ENDOCRINE GLAND; ENZYME LINKED IMMUNOSORBENT ASSAY; FEBRILE NONHAEMOLYTIC TRANSFUSION REACTION; FLOW CYTOMETRY; GENE EXPRESSION; GRANULOCYTE; HEMATOLOGIC DISEASE; HLA MATCHING; HLA SYSTEM; HUMAN; IMMUNOLOGICAL PLATELET REFRACTORINESS; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; LABORATORY TEST; LEUKAPHERESIS; LEUKEMIA; LEUKOCYTE; LEUKOPENIA; MORTALITY; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NERVE CELL; NONHUMAN; PLASMA TRANSFUSION; PLASMAPHERESIS; POLYMERASE CHAIN REACTION; POLYMERASE CHAIN REACTION SEQUENCE SPECIFIC OLIGONUCLEOTIDE PROBING; POLYMERASE CHAIN REACTION SEQUENCE SPECIFIC PRIMING; PREGNANCY; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE; THORAX RADIOGRAPHY; THROMBOCYTE; THROMBOCYTE DISORDER; THROMBOCYTE LIFESPAN; THROMBOCYTE TRANSFUSION; TISSUE DISTRIBUTION; TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE; TRANSFUSION RELATED ACUTE LUNG INJURY; TRANSFUSION RELATED IMMUNOMODULATION; TRANSPLANTATION;

BLOOD TRANSFUSION; HLA ANTIGENS; HUMANS;

EID: 79960262935     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2011.01474.x     Document Type: Review

References (88)

1. Lechler RI, Garden OA, Turka LA: The complementary roles of deletion and regulation in transplantation tolerance. Nat Rev Immunol 2003; 3:147-158.
2. Afzali B, Lechler RI, Hernandez-Fuentes MP: Allorecognition and the alloresponse: clinical implications. Tissue Antigens 2007; 69:545-556.
3. Navarrete C: The HLA system in blood transfusion; in Contreras M (ed.): New Aspects of Blood Transfusion. London, Baillière's Clinical Haematology, 2000.
4. Traherne JA: Human MHCarchitecture and evolution: implications for disease association studies. Int J Immunogenet 2008; 35:179-192.
5. Zou Y, Mirbaha F, Stastny P: Contact inhibition causes strong downregulation of expression of mica in human fibroblasts and decreased NK cell killing. Hum Immunol 2006; 67:183-187.
6. Groh V, Steinle S, Bauer S, et al.: Recognition of stress-induced MHC molecules by intestinal epithelial γδ T cells. Science 1998; 279:1737-1740.
7. Klein J, Sato A: The HLA system. N Engl J Med 2000; 343:702-709.
8. Puppo F, Ghio M, Contini P, et al.: Immunoregulatory role of soluble HLA molecules: a new skin for an old subject? Arch Immunol Ther Exp 1998; 46:157-160.
9. Bukulmez H, Fife M, Tsoras M, et al.: Tapasin gene polymorphism in systemic onset juvenile rheumatoid arthritis: a family-based case-control study. Arthritis Res Ther 2005; 7:R285-R290.
10. Horton R, Wilming L, Rand V, et al.: Gene map of the extended human MHC. Nat Rev Genet 2004; 5:889-899.
11. Ouwehand W, Navarrete C: The molecular basis of blood cell alloantigens; in Proven D, Gribben J (eds): Molecular Haematology. Oxford, Blackwell Science, 2005.
12. Howell WM, Carter V, Clark B: The HLA system: immunobiology, HLA typing, antibody screening and crossmatching techniques. J Clin Pathol 2010; 63:387-390.
13. Morales-Buenrostro LE, Terasaki PI, Marino-Vázquez LA, et al.: "Natural" human leukocyte antigen antibodies found in non alloimmunized healthy males. Transplantation 2008; 86:1111-1115.
14. Ravindranath MH, Taniguchi M, Chen CW, et al.: HLA-E monoclonal antibodies recognize shared peptide sequences on classical HLA class Ia: relevance to human natural HLA antibodies. Mol Immunol 2010; 47:112111-112131.
15. Levin MD, de Veld J, van der Holt B, et al.: Screening for alloantibodies in the serum of patients receiving platelet transfusions: a comparison of the ELISA, lymphocytotoxicity, and the indirect immunofluorescence method. Transfusion 2003; 43:72-77.
16. Tait BD, Hudson F, Cantwell L, et al.: Review article: Luminex technology for HLA antibody detection in organ transplantation. Nephrology (Carlton) 2009; 14:247-254.
17. Opelz G, Döhler B: Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades. Transplantation 2007; 84:137-143.
18. Petersdorf EW: Optimal HLA matching in hematopoietic cell transplantation. Curr Opin Immunol 2008; 20:588-593.
19. Brand A: Immunological aspects of blood transfusions. Blood Rev 2000; 14:130-144.
20. Taylor C, Navarrete C, Contreras M: Immunological complications of transfusion; in Maniatis A, Van der Linden P, Hardy JF (eds): Alternatives to Blood Transfusion in Transfusion Medicine. Oxford, Wiley-Blackwell, 2010:31-47.
21. Semple JW, Speck ER, Cosgrave D, et al.: Extreme leukoreduction of major histocompatibility complex class II positive B cells enhances allogeneic platelet immunity. Blood 1999; 93:713-720.
22. Bao W, Yu J, Heck S, et al.: Regulatory T-cell status in red cell alloimmunized responder and nonresponder mice. Blood 2009; 113:5625-5627.
23. Higgins JM, Sloan SR: Stochastic modelling of human RBC alloimmunization: evidence for a distinct population of immunologic responders. Blood 2008; 112:2546-2553.
24. Brubaker DB: Clinical significance of white cell antibodies in febrile non-hemolytic transfusion reactions. Transfusion 1990; 30:733-737.
25. Tazzari PL, Bontadini A, Zamagni C, et al.: Febrile non-haemolytic transfusion reaction caused by antibodies against human platelet antigen 5a. Transfus Med 2005; 15:443-444.
26. Fadeyi EA, Adams S, Sheldon S, et al.: A preliminary comparison of the prevalence of transfusion reactions in recipients of platelet components from donors with and without human leucocyte antigen antibodies. Vox Sang 2008; 94:324-328.
27. Paglino JC, Pomper GJ, Fisch GS, et al.: Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal pre-storage leukoreduction. Transfusion 2004; 44:16-24.
28. Heddle NM: Pathophysiology of febrile non-hemolytic transfusion reactions. Curr Opin Hematol 1999; 6:420-426.
29. Heddle NM: Febrile non-hemolytic transfusion reactions to platelets. Curr Opin Hematol 1995; 6:478-483.
30. Chudziak D, Sireis W, Pfeiffer HU, et al.: Accumulation of soluble inflammatory mediators between blood donation and pre-storage leucocyte depletion. Vox Sang 2009; 96:163-166.
31. Blumberg N, Gettings KF, Turner C, et al.: An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions. Transfusion 2006; 46:1813-1821.
32. Kiefel V, König C, Kroll H, et al.: Platelet alloantibodies in transfused patients. Transfusion 2001; 41:766-770.
33. Sanz C, Freire C, Alcorta I, et al.: Platelet-specific antibodies in HLA-immunized patients receiving chronic platelet support. Transfusion 2001; 41:762-765.
34. Brand A: Alloimmune platelet refractoriness: incidence declines, unsolved problems persist. Transfusion 2001; 41:724-726.
35. Carr R, Hutton JL, Jenkins JA, et al.: Transfusion of ABO-mismatched platelets leads to early platelet refractoriness. Br J Haematol 1995; 75:408-413.
36. McVey M, Cserti-Gazdewich CM: Platelet transfusion refractoriness responding preferentially to single donor apheresis platelets compatible for both ABO and HLA. Transfus Med 2010; 20:346-353.
37. Bang WA, Speck ER, Blanchette VS, et al.: Unique processing pathways within recipient antigen-presenting cells determine IgG immunity against donor platelet MHC antigens. Blood 2000; 95:1735-1742.
38. Duquesnoy RJ, White LT, Fierst JW, et al.: Multiscreen serum analysis of highly sensitized renal dialysis patient for antibodies toward public and private class I HLA determinants. Transplantation 1990; 50:427-437.
39. Park MS, Barbetti AA, Geer L, et al.: HLA class I epitopes selected by serology; in Terasaki PI (ed): Clinical Transplants. Los Angeles, UCLA Tissue Typing Laboratory, 1990.
40. Duquesnoy RJ: HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. I. Description of the algorithm. Hum Immunol 2002; 63:339-352.
41. Duquesnoy RJ, Marrari M: HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. II. Verification of the algorithm and determination of the relative immunogenicity of amino acid triplet-defined epitopes. Hum Immunol 2002; 63:353-363.
42. Duquesnoy RJ, Mulder A, Askar M, et al.: HLAMatchmaker-based analysis of human monoclonal antibody reactivity demonstrates the importance of an additional contact site for specific recognition of triplet-defined epitopes. Hum Immunol 2005; 66:749-761.
43. Vassallo RR Jr: New paradigms in the management of alloimmune refractoriness to platelet transfusions. Curr Opin Hematol 2007; 14:655-663.
44. Bux J: Transfusion-related acute lung injury (TRALI): a serious adverse event of blood transfusion. Vox Sang 2005; 89:1-10.
45. Skeate RC, Eastlund T: Distinguishing between transfusion related acute lung injury and transfusion associated circulatory overload. Curr Opin Hematol 2007; 14:682-687.
46. Kleinman S, Caulfield T, Chan P, et al.: Toward an understanding of transfusion related acute lung injury: statement of a consensus panel. Transfusion 2004; 44:1774-1789.
47. Davis A, Mandal R, Johnson M, et al.: A touch of TRALI. Transfusion 2008; 48:541-545.
48. Kopko PM, Popovsky MA, MacKenzie MR, et al.: HLA class II antibodies in transfusion-related acute lung injury. Transfusion 2001; 41:1244-1248.
49. Win N, Massey E, Lucas G, et al.: Ninety-six suspected transfusion related acute lung injury cases: investigation findings and clinical outcome. Hematology 2007; 12:461-469.
50. Chapman CE, Stainsby D, Jones H, et al.: Serious hazards of transfusion steering group: ten years of haemovigilance reports of the transfusion-related acute lung injury in the UK, and the impact of preferential use of male donor plasma. Transfusion 2009; 49:440-452.
51. Middelburg RA, van Stein D, Briët E, et al.: The role of donor antibodies in the pathogenesis of transfusion-related acute lung injury: a systematic review. Transfusion 2008; 48:2167-2176.
52. Bux J, Becker F, Seeger W, et al.: Transfusion-related acute lung injury due to HLA-A2-specific antibodies in recipient and NB1-specific antibodies in donor blood. Br J Haematol 1996; 93:707-713.
53. Lucas G, Rogers S, Evans R, et al.: Transfusion-related acute lung injury associated with interdonor incompatibility for the neutrophil-specific antigen HNA-1a. Vox Sang 2000; 79:112-115.
54. Win N, Chapman CE, Bowles KM, et al.: How much residual plasma may cause TRALI? Transfus Med 2008; 18:276-280.
55. Silliman CC, Bjornsen AJ, Wyman TH, et al.: Plasma and lipids from stored platelets cause acute lung injury in an animal model. Transfusion 2003; 43:633-640.
56. Kelher MR, Masuno T, Moore E, et al.: Plasma from stored packed red blood cells and MHC class I antibodies causes acute lung injury in a 2-event in vivo rat model. Blood 2009; 113:2079-2087.
57. Cruz J, Skipworth E, Blue D, et al.: Transfusion-related acute lung injury: a thrombotic thrombocytopenic purpura treatment-associated case report and concise review. J Clin Apher 2008; 23:96-103.
58. Silliman CC, Boshkov LK, Mehdizadehkashi Z, et al.: Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors. Blood 2003; 101:454-462.
59. Silliman CC, Ambruso DR, Boshkov LK: Transfusion related acute lung injury. Blood 2005; 105:2266-2273.
60. Fung YL, Kim M, Tabuchi A, et al.: Recipient T lymphocytes modulate the severity of antibody-mediated transfusion-related acute lung injury (TRALI). Blood 2010; 116:3073-3079.
61. Ware LB, Matthay MA: The acute respiratory distress syndrome. N Engl J Med 2000; 342:1334-1349.
62. Popovsky MA, Chaplin HC Jr, Moore SB: Transfusion related acute lung injury: a neglected serious complication of hemotherapy. Transfusion, 1992; 32:589-592.
63. Eder AF, Herron RM Jr, Strupp A, et al.: Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006-2008). Transfusion 2010; 50:1732-1742.
64. Nakazawa H, Ohnishi H, Hashimoto S, et al.: Impact of fresh frozen plasma from male- only donors versus mixed sex donors on postoperative respiratory function in surgical patients: a prospective case-controlled study. Transfusion 2009; 49:2434-2441.
65. Agbaht K, Altintas ND, Topeli A, et al.: Transfusion-associated graft-versus-host disease in immunocompetent patients: case series and review of the literature. Transfusion 2007; 47:1405-1411.
66. Wisecarver JL, Cattral MS, Langnas A, et al.: Transfusion-induced graft-versus-host disease after liver transplantation. Transplantation 1994; 58:269-271.
67. Rososhansky S, Badonnel MCH, Hiestand LL, et al.: Transfusion-associated graft-versus-host disease in an immunocompetent patient following after cardiac surgery. Vox Sang 1999; 76:59-63.
68. Dunne JR, Lee TH, Burns C, et al.: Transfusion-associated microchimerism in combat casualties. J Trauma 2008; 64:S92-S97; discussion S97-S98.
69. Nishimura M, Uchida S, Mitsunaga S, et al.: Characterization of T-cell clones derived from peripheral blood lymphocytes of a patient with transfusion-associated graft-versus-host disease: Fas-mediated killing by CD4+ and CD8+ cytotoxic T-cell clones and tumour necrosis factor β production by CD4+ T-cell clones. Blood 1997; 89:1440-1445.
70. Hill GR, Krenger W, Ferrara JL: The role of cytokines in acute graft-versus-host disease. Cytokines Cell Mol Ther 1997; 3:257-266.
71. Sage D, Stanworth S, Turner D, et al.: Diagnosis of transfusion-associated graft-vs.-host disease: the importance of short tandem repeat analysis. Transfus Med 2005; 15:481-485.
72. Link H: T-cell depletion of allogeneic peripheral blood stem cells; in Gorin N-C (ed.): Baillière's Clinical Haematology. Best Pract. Res. Clin. Haematol. 1999; 12:87-98.
73. Williamson LM, Stainsby D, Jones H, et al.: The impact of universal leukodepletion of the blood supply on haemovigilance reports of post-transfusion purpura and transfusion-associated graft-versus-host disease. Transfusion 2007; 47:1455-1467.
74. Przepiorka D, LeParc GF, Stovall MA, et al.: Use of irradiated blood components: practice parameter. Am J Clin Pathol 1996; 106:6-11.
75. Chapman J, Finney RD, Forman K, et al.: Guidelines on gamma irradiation of blood components for the prevention of transfusion-associated graft-versus-host disease. Transfus Med 1996; 6:261-271.
76. Blajchman MA, Dzik S, Vamvakas EC, et al.: Clinical and molecular basis of transfusion-induced immunomodulation: summary of the proceedings of a state-of-the-art conference. Transfus Med Rev 2001; 15:108-135.
77. Opelz G, Sengar DP, Mickey MR: Effect of blood transfusions on subsequent kidney transplants. Transpl Proc 1973; 5:253-259.
78. Gharesi-Fard B, Zolghadri J, Foroughinia L, et al.: Effectiveness of leukocyte immunotherapy in primary recurrent spontaneous abortion (RSA). Iran J Immunol 2007; 4:173-178.
79. Opelz G, Vanrenterghem Y, Kirste G, et al.: Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients. Transplantation 1997; 63:964-967.
80. Gianotti L, Pyles T, Alexander JW, et al.: Identification of the blood component responsible for increased susceptibility to gut-derived infection. Transfusion 1993; 33:458-465.
81. Mynster T, Dybkjoer E, Kronborg G, et al.: Immunomodulating effect of blood transfusion: is storage time important? Vox Sang 1998; 74:176-181.
82. Babcock GF, Alexander AJ: The effects of blood transfusion on cytokine production by Th1 and Th2 lymphocytes in the mouse. Transplantation 1996; 61:465-468.
83. Kalechman Y, Gafter U, Sobelman D, et al.: The effect of a single whole-blood transfusion on cytokine secretion. J Clin Immunol 1990; 10:99-105.
84. Ghio M, Contini P, Mazzei C, et al.: Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood 1999; 93:1770-1777.
85. Zavazava N, Krönke M: Soluble HLA class I molecules induce apoptosis in alloreactive cytotoxic T lymphocytes. Nat Med 1996; 2:1005-1010.
86. Carbone E, Terrazzano G, Colonna M, et al.: Natural killer clones recognize specific soluble HLA class I molecules. Eur J Immunol 1996; 26:683-689.
87. Duquesnoy RJ: Structural epitope matching for HLA-alloimmunized thrombocytopenic patients: a new strategy to provide more effective platelet transfusion support? Transfusion 2008; 48:221-227.
88. Figueiredo C, Goudeva L, Horn PA, et al.: Generation of HLA-deficient platelets from hematopoietic progenitor cells. Transfusion 2010; 50:1690-1701.